COVID-19

Tu5 - Serum IL-6 and PTX3 Predict Severe Outcome from Covid-19 in Ambulatory Subjects

W65 - Longitudinal Dynamics of SARS-CoV-2 Specific Cellular Immunity to Different Vaccination Schemes

W70 - SARS-CoV-2 Rapid Antigen Kit Efficacy in Comparison with Quant Studio 12 PCR Poster

W71 - SARS-CoV-2 Neutralizing Antibody Presence in Infected and Vaccinated Patients

W75 - A 10-Month Period Evaluation of Cellular Responses After ChAdOx1-nCoV-19 and BNT162b2 Vaccinations

W87 - A Versatile New Monoclonal Antibody for Elucidating Human TMPRSS2 Expression and Function

W90 - CSF Inflammatory and Neuroaxonal Damage Biomarkers in COVID-19 Associated Encephalopathy and Encephalitis

Tu15 - Elevated anti-PEG Antibody Levels Amongst Covid-19 Vaccinated Donors

Tu21 - Monitoring of Naturally Acquired and Vaccine-induced SARS-CoV-2 Specific Cellular Immune Responses

Tu36 - SARS-CoV-2-specific T Cells in Unexposed Adults Display Broad Trafficking Potential and Cross-react with Commensal Antigens

Tu38 - CLEC5A and TLR2 are Critical in SARS-CoV-2-induced Immunothrombosis and Lung Inflammation

Tu40 - Humoral Response to Heterologous Prime-boost Vaccination with CoronaVac and BNT162b2 in Healthy Individuals and Solid Organ Transplant Recipients

Tu46 - Quantitative Analysis of SARS-CoV-2 Antibody Titer After the 3rd Dose of COVID-19 Vaccination

Tu53 - Rapid Waning and Unique Response Kinetics of Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients on Immunomodulatory Drugs

Tu56 - Analysis of Antigen-Specific Cellular and Humoral Immune Response in COVID-19 Patients

Tu96 - Epitope Profiling of COVID-19 Convalescent Plasma and Vaccine Elicited Antibodies

W112 - B Cell Subsets as Severity-associated Signatures in COVID-19 Patients

W125 - SARS-CoV-2 Antibody Kinetics in Healthcare Workers in Northern Metropolitan Barcelona

W175 - Immunological Profiles of HIV-infected and Uninfected Patients Admitted with COVID-19 in Tshwane

W185 - Fc Structure and Function of Antibodies Elicited by COVID-19 mRNA Vaccine and Infection

Tu111 - Severity of SARS-CoV-2 Infection is Linked to Double Negative (CD27- IgD-) B Cell Subsets Numbers

Tu126 - Efficacy and Safety of mRNA SARS-CoV-2 Vaccination in Hematopoietic Stem Cell Transplant Recipients: Single Centre Experience

Tu137 - Allogenic and Autologous Stem Cell Transplant (SCT) Recipients have Detectable Levels of SARS-CoV-2 Antigen-specific T Cells One Month After mRNA Vaccination

Tu138 - Sequence Similarity Between SARS-CoV-2 Nucleocapsid and CNS Proteins Provides Mechanistic Insight into Viral Neuropathogenesis Following Infection

Tu158 - TNFα-producing CD4+ T Cells Dominate the SARS-CoV-2-specific T Cell Response in COVID-19 Outpatients and are Associated with Durable Antibodies

Tu228 - Comprehensive assessment of SARS-CoV-2 antibodies after COVID-19 infection and vaccination (BNT162b2 or ChAdOx1 nCoV-19) using multiplex bead assay